Download File - JOHN J. HADDAD, Ph.D.

Table 1 Investigational Peptide-Based Vaccines (Continued )
Development
stage Biological/clinical activity Reference
Antigen Tumor type Strategy
Peptide-Based Active Immunotherapy in Cancer 115
34
80
65
MART-1/Melan-A Melanoma Monotherapy Phase I No tumor regression observed. An enhancement of
the cytotoxic activity against MART-1/Melan-A
was detected
MART-1/Melan-A, Melanoma Combinatorial Phase I Six of 12 patients developed a positive skin test
gp100, and
(SD-9427—a
response to the peptides. Seven of 10 patients had
tyrosinase
GM-CSF
an immune response to at least one peptide when
agonist)
evaluated via IFN-gamma release assay and
ELISPOT assay, so did 11 of 12 patients analyzed
by MHC-peptide tetramer assay
MART-1/Melan-A Melanoma Monotherapy Phase I Ten of 22 patients had response to peptide-pulsed
targets or tumor cells by ELISA assay after
vaccination. Twelve of 20 patients had response by
ELISPOT. Immune response by ELISA correlated
with prolonged relapse-free survival
MART-1/Melan-A Melanoma Combinatorial Phase II Out of 20 patients, two patients had a complete
(IL-12)
response, five had a minor or mixed response, and
four patients had stable disease. There was a
correlation between the magnitude of the increase
in MART-1/Melan-A–specific cells and clinical
response
MART-1/Melan-A, Melanoma Combinatorial Phase I/II Peptides were more effective when given with the
tyrosinase,
(Montanide-
adjuvant Montanide-ISA-720
MAGE-3
ISA-720
adjuvant,
GM-CSF)
77
79
(Continued )